Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
October 04, 2023 16:05 ET
|
Revolution Medicines, Inc.
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m....
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023 07:00 ET
|
Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
Blue Star Foods Repays Convertible Note
September 18, 2023 08:30 ET
|
Blue Star Foods Corp.
Miami, FL, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023 16:05 ET
|
Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
August 08, 2023 16:05 ET
|
Revolution Medicines, Inc.
Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple...
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 03, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Refinery Process Additives Market to Hit US$ 3,305.73 Million By 2030 | Consegic Business Intelligence
July 19, 2023 06:00 ET
|
CONSEGIC BUSINESS INTELLIGENCE PRIVATE LIMITED
New York, July 19, 2023 (GLOBE NEWSWIRE) -- The global Refinery Process Additives Market is expected to witness significant growth at a remarkable CAGR of 6.8% during the forecast period of...
Blue Star Foods Regains Compliance with NASDAQ Minimum Bid Price Requirement
July 13, 2023 08:30 ET
|
Blue Star Foods Corp.
Miami, FL, July 13, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...
Blue Star Foods Granted Option to Purchase Land for RAS Expansion in South Carolina
June 30, 2023 08:30 ET
|
Blue Star Foods Corp.
Miami, FL, June 30, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...
Blue Star Foods Strengthens Balance Sheet by Paying Off its $5 Million Asset Based Line of Credit to Zero Balance
June 22, 2023 08:30 ET
|
Blue Star Foods Corp.
Miami, FL, June 22, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated Environmental, Social, and Governance (ESG)...